vs

Side-by-side financial comparison of Strategy Inc (MSTR) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

Strategy Inc is the larger business by last-quarter revenue ($123.0M vs $75.5M, roughly 1.6× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 1.9%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 3.3%).

Strategy Inc., formerly known as MicroStrategy, is an American company that provides business intelligence (BI) and mobile software. Founded in 1989 by Michael J. Saylor, Sanju Bansal, and Thomas Spahr, the firm develops software to analyze internal and external data in order to make business decisions and to develop mobile apps. It is a public company headquartered in Tysons Corner, Virginia, in the Washington metropolitan area. Its primary business analytics competitors include SAP SE Busin...

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

MSTR vs PBYI — Head-to-Head

Bigger by revenue
MSTR
MSTR
1.6× larger
MSTR
$123.0M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+25.8% gap
PBYI
27.7%
1.9%
MSTR
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
3.3%
MSTR

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
MSTR
MSTR
PBYI
PBYI
Revenue
$123.0M
$75.5M
Net Profit
Gross Margin
66.1%
69.3%
Operating Margin
22.7%
Net Margin
Revenue YoY
1.9%
27.7%
Net Profit YoY
EPS (diluted)
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MSTR
MSTR
PBYI
PBYI
Q4 25
$123.0M
$75.5M
Q3 25
$128.7M
$54.5M
Q2 25
$114.5M
$52.4M
Q1 25
$111.1M
$46.0M
Q4 24
$120.7M
$59.1M
Q3 24
$116.1M
$80.5M
Q2 24
$111.4M
$47.1M
Q1 24
$115.2M
$43.8M
Net Profit
MSTR
MSTR
PBYI
PBYI
Q4 25
Q3 25
$2.8B
$8.8M
Q2 25
$10.0B
$5.9M
Q1 25
$-4.2B
$3.0M
Q4 24
$-670.8M
Q3 24
$-340.2M
$20.3M
Q2 24
$-102.6M
$-4.5M
Q1 24
$-53.1M
$-4.8M
Gross Margin
MSTR
MSTR
PBYI
PBYI
Q4 25
66.1%
69.3%
Q3 25
70.5%
77.7%
Q2 25
68.8%
76.5%
Q1 25
69.4%
77.1%
Q4 24
71.7%
76.4%
Q3 24
70.4%
63.9%
Q2 24
72.2%
77.4%
Q1 24
74.0%
75.5%
Operating Margin
MSTR
MSTR
PBYI
PBYI
Q4 25
22.7%
Q3 25
17.6%
Q2 25
12.7%
Q1 25
-5331.4%
8.7%
Q4 24
-842.1%
22.6%
Q3 24
-372.7%
27.4%
Q2 24
-179.7%
-4.6%
Q1 24
-176.8%
-5.3%
Net Margin
MSTR
MSTR
PBYI
PBYI
Q4 25
Q3 25
2164.1%
16.2%
Q2 25
8752.7%
11.2%
Q1 25
-3797.2%
6.5%
Q4 24
-555.8%
Q3 24
-293.1%
25.2%
Q2 24
-92.0%
-9.6%
Q1 24
-46.1%
-11.0%
EPS (diluted)
MSTR
MSTR
PBYI
PBYI
Q4 25
$0.26
Q3 25
$8.42
$0.17
Q2 25
$32.60
$0.12
Q1 25
$-16.49
$0.06
Q4 24
$4.49
$0.40
Q3 24
$-1.72
$0.41
Q2 24
$-0.57
$-0.09
Q1 24
$-0.31
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MSTR
MSTR
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$2.3B
$97.5M
Total DebtLower is stronger
$8.2B
$22.7M
Stockholders' EquityBook value
$44.1B
$130.3M
Total Assets
$61.6B
$216.3M
Debt / EquityLower = less leverage
0.19×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MSTR
MSTR
PBYI
PBYI
Q4 25
$2.3B
$97.5M
Q3 25
$54.3M
$94.4M
Q2 25
$50.1M
$96.0M
Q1 25
$60.3M
$93.2M
Q4 24
$38.1M
$101.0M
Q3 24
$46.3M
$96.7M
Q2 24
$66.9M
$96.8M
Q1 24
$81.3M
$107.2M
Total Debt
MSTR
MSTR
PBYI
PBYI
Q4 25
$8.2B
$22.7M
Q3 25
$8.2B
$34.0M
Q2 25
$8.2B
$45.3M
Q1 25
$8.1B
$56.7M
Q4 24
$7.2B
$68.0M
Q3 24
$4.2B
$79.3M
Q2 24
$3.8B
$90.7M
Q1 24
$3.6B
$102.0M
Stockholders' Equity
MSTR
MSTR
PBYI
PBYI
Q4 25
$44.1B
$130.3M
Q3 25
$52.3B
$115.3M
Q2 25
$47.5B
$104.7M
Q1 25
$32.2B
$97.1M
Q4 24
$18.2B
$92.1M
Q3 24
$3.8B
$71.1M
Q2 24
$2.8B
$48.5M
Q1 24
$2.4B
$51.0M
Total Assets
MSTR
MSTR
PBYI
PBYI
Q4 25
$61.6B
$216.3M
Q3 25
$73.6B
$202.9M
Q2 25
$64.8B
$194.9M
Q1 25
$43.9B
$196.2M
Q4 24
$25.8B
$213.3M
Q3 24
$8.3B
$220.7M
Q2 24
$7.1B
$205.0M
Q1 24
$6.4B
$214.1M
Debt / Equity
MSTR
MSTR
PBYI
PBYI
Q4 25
0.19×
0.17×
Q3 25
0.16×
0.30×
Q2 25
0.17×
0.43×
Q1 25
0.25×
0.58×
Q4 24
0.39×
0.74×
Q3 24
1.12×
1.12×
Q2 24
1.36×
1.87×
Q1 24
1.48×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MSTR
MSTR
PBYI
PBYI
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MSTR
MSTR
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$-8.3M
$9.7M
Q2 25
$-34.9M
$14.1M
Q1 25
$-2.4M
$3.6M
Q4 24
$-17.3M
$15.6M
Q3 24
$-41.0M
$11.0M
Q2 24
$-23.3M
$1.0M
Q1 24
$28.6M
$11.2M
Free Cash Flow
MSTR
MSTR
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$-11.1M
$9.7M
Q2 25
$-37.0M
$14.1M
Q1 25
$-5.1M
$3.6M
Q4 24
$-17.6M
$15.6M
Q3 24
$-41.4M
$11.0M
Q2 24
$-24.1M
$1.0M
Q1 24
$27.0M
FCF Margin
MSTR
MSTR
PBYI
PBYI
Q4 25
19.1%
Q3 25
-8.6%
17.7%
Q2 25
-32.3%
26.8%
Q1 25
-4.6%
7.7%
Q4 24
-14.6%
26.4%
Q3 24
-35.7%
13.7%
Q2 24
-21.6%
2.1%
Q1 24
23.5%
Capex Intensity
MSTR
MSTR
PBYI
PBYI
Q4 25
0.0%
Q3 25
2.2%
0.0%
Q2 25
1.8%
0.0%
Q1 25
2.5%
0.1%
Q4 24
0.2%
0.0%
Q3 24
0.4%
0.0%
Q2 24
0.6%
0.0%
Q1 24
1.3%
0.0%
Cash Conversion
MSTR
MSTR
PBYI
PBYI
Q4 25
Q3 25
-0.00×
1.10×
Q2 25
-0.00×
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons